This finding provides reassurance that estradiol levels are not significantly altered during treatment with an oral NK3R antagonist and therefore may be practice-changing as it could give physicians the confidence to prescribe such agents to otherwise long-suffering women with a history of hormonally receptive breast cancer or those on estrogen deprivation therapy. The gene discussed is TACR3; the disease is breast carcinoma.